Bookmark
Forward
Explore Literature Results
QuickView for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=ED732D6F8E2B55D44E4470C64FCAE073;jsessionid=369D0FFBC2D87636BB1B0994D6332FBD;jsessionid=86EE8D8B6B703E6EEBA3A5B918311149;jsessionid=721D62B3A270ACC6D9EF9470B56D2FF2;jsessionid=777569317CCAAF6560E300AE323F785B;jsessionid=0B26DA522EF2C3E6BD93409E647D84F3;jsessionid=19A769D966BDD6E069066D68F340786F;jsessionid=7C1285677A9BF9BAF049A6A0816B439E (gene)
Most Relevant Literature
- Computational analysis predicts the Kaposi's sarcoma-associated herpesvirus tegument protein ORF63 t…
- Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma G…
- Stability of varicella-zoster virus open reading frame 63.
- Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons.
- Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for…
Most Relevant Clinical Trials
There were no clinical trials for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=ED732D6F8E2B55D44E4470C64FCAE073;jsessionid=369D0FFBC2D87636BB1B0994D6332FBD;jsessionid=86EE8D8B6B703E6EEBA3A5B918311149;jsessionid=721D62B3A270ACC6D9EF9470B56D2FF2;jsessionid=777569317CCAAF6560E300AE323F785B;jsessionid=0B26DA522EF2C3E6BD93409E647D84F3;jsessionid=19A769D966BDD6E069066D68F340786F;jsessionid=7C1285677A9BF9BAF049A6A0816B439E
Explore Clinical Trials Results
